Morphic Reports P-IIa Trial (EMERALD-1) Results of c for the Treatment of Ulcerative Colitis
Shots:
- The company also highlighted the results from the main cohort of the P-IIa trial (EMERALD-1) evaluating MORF-057, an oral small molecule inhibitor of the α4β7 integrin in 35 adults with mod. to sev. UC at sites in the US & Poland
- MORF-057 achieved the 1EPs & showed that patients treated with MORF-057 experienced a reduction in the RHI score of 6.4 points from baseline to 12wk., 25.7% clinical remission rate as measured by mMCS, mMCS response rate (45.7%) & mean α4β7 receptor occupancy (>98%)
- The therapy was well tolerated at the dose of 100mg, BID with no SAEs & no safety signal. The P-IIb study (EMERALD-2) of MORF-057 is currently enrolling patients for the same indication
Ref: Morphic | Image: Morphic
Related News:- Engitix and Morphic Collaborate to Detect ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
